We remain focused on advancing GTX104 and prioritizing capital efficiency while pursuing non-dilutive and strategic funding alternatives where practical.
— Management (paraphrase from SEC filing)
03Detailed Report
GRCE
Grace Therapeutics Inc
Period
Q3 2026
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 24, 2026
Swipe to view all report sections
Executive Summary
Grace Therapeutics (GRCE) reported another pre-revenue quarter for Q3 2026. The company remains a clinical-stage biotechnology developer with no product sales. Operating loss for the quarter was $3.36M and net loss was $3.18M (EPS -$0.19). Operating cash flow was negative $2.22M. Cash and equivalents of $18.67M at quarter-end provide a multi-quarter runway but will require further financing to fund continued clinical development and commercialization activities beyond the medium term. The balance sheet carries substantial intangible assets (reported at $41.13M) and goodwill ($8.14M), which warrants monitoring for potential impairment given the absence of revenues. Key near-term value drivers are clinical progress and regulatory interactions for GTX104 and pipeline programs; key risks are trial outcomes, further dilution and the need to secure additional capital.
Key Performance Indicators
Operating Income
Increasing
-3.36M
QoQ: 4.73% | YoY: 30.44%
Net Income
Increasing
-3.18M
QoQ: -142.80% | YoY: 7.45%
EPS
Increasing
-0.19
QoQ: -131.14% | YoY: 36.67%
Revenue Trend
Margin Analysis
Financial Highlights
Reporting currency: USD. Quarter ended 2025-12-31 (Q3 2026). Revenue: none (pre-revenue). R&D: $0.63M. G&A: $2.72M. Operating loss: $(3.36)M. Net loss: $(3.18)M; EPS: $(0.19) on 16.933M weighted average shares. EBITDA: $(3.36)M. Operating cash flow: $(2.22)M. Free cash flow: $(2.22)M. Cash & equivalents: $18.67M. Total assets: $68.49M. Total liabilities: $3.60M. Stockholders' equity: $64.89M. Intangible assets: $41.13M; goodwill: $8.14M. Deferred tax liabilities (non-current): $2.31M. Common stock issued (period financing): $5.51M (cash inflow). Estimated cash runway (based on current quarterly operating cash outflow): ~8.4 quarters (~2.1 years), subject to timing of investing and financing activity and clinical spend variability.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-3.36M
30.44%
4.73%
Net Income
-3.18M
7.45%
-142.80%
EPS
-0.19
36.67%
-131.14%
Key Financial Ratios
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.